1st Respiratory Medicine Department, Medical School, National and Kapodistrian University of Athens, Sotiria Chest Diseases Hospital, Mesogeion 152, 11527 Athens, Greece.
5th Respiratory Medicine Department, Sotiria Chest Diseases Hospital, Mesogeion 152, 11527 Athens, Greece.
Cytokine. 2017 Nov;99:281-286. doi: 10.1016/j.cyto.2017.08.005. Epub 2017 Aug 31.
Bronchiectasis is a heterogeneous entity, taking into account clinical characteristics, inflammatory response, effectiveness of treatment and frequency of exacerbations. In stable state non-cystic fibrosis (non-CF) bronchiectasis, little is known about non-invasive techniques used for evaluating airway inflammation in obstructive airway diseases.
We sought to evaluate the associations between induced sputum and clinical/radiologic characteristics, and the differences between biomarkers expressing Th1 and Th2 response in patients with non-CF bronchiectasis and to compare our findings with a previously studied population of patients with asthma and COPD.
We evaluated prospectively collected data from subjects with bronchiectasis. Comparisons were made between clinical, radiographic and physiologic characteristics, as well as induced sputum markers using appropriate statistical tools. We compared the levels of sputum markers with those of a previously studied cohort of asthma and COPD patients.
We enrolled 40 subjects (21men, mean age 63.5yrs) with bronchiectasis. Fifteen subjects (37.5%) had a neutrophilic phenotype, 7 (17.5%) had an eosinophilic phenotype, 3 (12.5%) had a mixed neutrophilic-eosinophilic phenotype and 15 (37.5%) had a paucigranulocytic phenotype. Subjects with sputum neutrophilia had more severe bronchiectasis in HRCT and higher levels of IL-8 in sputum, whereas subjects with eosinophilia had higher levels of FeNO, greater bronchodilator reversibility and higher sputum IL-13. Sputum IL-8 levels were higher in subjects exhibiting frequent exacerbations and correlated with neutrophils in sputum (r=0.799), the extent of bronchiectasis in HRCT (r=0.765) and post-bronchodilator FEV (r=-0.416). Sputum IL-13 levels correlated with sputum eosinophils (r=0.656) and bronchodilator reversibility (r=0.441). Neutrophilic bronchiectasis exhibited comparable IL-8 levels to COPD, whereas eosinophilic bronchiectasis showed significantly lower IL-13 levels compared to asthma.
Sputum cell counts and IL-8 and IL-13 correlate with distinct clinical and functional measurements of disease severity and therefore may have a role for non-invasively assessing inflammation in non-cystic fibrosis bronchiectasis.
支气管扩张症是一种异质性实体,考虑到临床特征、炎症反应、治疗效果和加重频率。在稳定状态下的非囊性纤维化(非 CF)支气管扩张症中,对于用于评估阻塞性气道疾病气道炎症的非侵入性技术知之甚少。
我们旨在评估诱导痰与非 CF 支气管扩张症患者的临床/放射学特征之间的相关性,并比较 Th1 和 Th2 反应标志物之间的差异,并将我们的发现与之前研究的哮喘和 COPD 患者人群进行比较。
我们前瞻性地评估了支气管扩张症患者的临床数据。使用适当的统计工具比较了临床、放射学和生理学特征以及诱导痰标志物。我们比较了痰液标志物与之前研究的哮喘和 COPD 患者队列的水平。
我们共纳入了 40 名患者(21 名男性,平均年龄 63.5 岁),其中 15 名(37.5%)为中性粒细胞表型,7 名(17.5%)为嗜酸性粒细胞表型,3 名(12.5%)为混合性中性粒细胞-嗜酸性粒细胞表型,15 名(37.5%)为少粒细胞表型。痰液中性粒细胞增多的患者 HRCT 显示支气管扩张更严重,痰液中 IL-8 水平更高,而嗜酸性粒细胞增多的患者 FeNO 水平更高,支气管扩张剂可逆性更大,痰液中 IL-13 水平更高。频繁加重的患者痰液 IL-8 水平较高,与痰液中的中性粒细胞呈正相关(r=0.799),HRCT 中支气管扩张的程度呈正相关(r=0.765),支气管扩张剂后 FEV 呈负相关(r=-0.416)。痰液 IL-13 水平与痰液嗜酸性粒细胞呈正相关(r=0.656),与支气管扩张剂可逆性呈正相关(r=0.441)。中性粒细胞性支气管扩张症的 IL-8 水平与 COPD 相当,而嗜酸性粒细胞性支气管扩张症的 IL-13 水平明显低于哮喘。
痰液细胞计数和 IL-8 和 IL-13 与疾病严重程度的不同临床和功能测量相关,因此可能在非囊性纤维化支气管扩张症中具有非侵入性评估炎症的作用。